These results reveal that the dephosphorylation and degradation of BCR-ABL by SPOA inhibit the signal transduction of BCR-ABL, which plays the anti-leukemia effect in CML cells, even with highly resistant T315I mutation. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.